The injury response of oligodendrocyte precursor cells is induced by platelets, macrophages and inflammation-associated cytokines.
Oligodendrocyte precursor cells recognized with the NG2 antibody respond rapidly to CNS injuries with hypertrophy and upregulation of the NG2 chondroitin sulfate proteoglycan within 24 h. These cells participate in glial scar formation, remaining around the injury site for several weeks. After injury, reactive oligodendrocyte precursor cells increase their production of several chondroitin sulfate proteoglycans, including NG2: this cell type thus represents a component of the inhibitory environment that prevents regeneration of axons in the injured CNS. This study analyzes factors that activate oligodendrocyte precursor cells. Both microglia and astrocytes become reactive around motor neurons following peripheral nerve lesions. We show that oligodendrocyte precursor cells do not hypertrophy or increase NG2 levels after these lesions. Those lesions that cause an oligodendrocyte precursor cell reaction generally open the blood-brain barrier. We therefore opened the blood-brain barrier with microinjections of vascular endothelial growth factor or lipopolysaccharide to the rat and mouse brain, and examined oligodendrocyte precursor cell reactivity after 24 h. Both treatments led to increases in NG2 and hypertrophy of oligodendrocyte precursor cells. Of directly injected blood components serum and thrombin were without effect, while platelets and macrophages activated oligodendrocyte precursor cells. We tested the effects of a range of injury-related cytokines, of which tumor necrosis factor alpha; interleukin-1; transforming growth factor beta; interferon gamma had effects on oligodendrocyte precursor cells. Oligodendrocyte precursor cell chemokines, and mitogens did not increase NG2 levels.
Rhodes
K E
KE
Cambridge University Centre for Brain Repair, University of Cambridge, Forvie Site, Robinson Way, Cambridge CB2 2PY, UK.
Raivich
G
G
Fawcett
J W
JW
D000818:Animals; D000941:Antigens / Q000378:metabolism; D019771:Axotomy / Q000379:methods; D001792:Blood Platelets / Q000502:physiology*; D001812:Blood-Brain Barrier / Q000187:drug effects / Q000503:physiopathology; D001921:Brain / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D039481:CD11b Antigen / Q000378:metabolism; D002460:Cell Line; D016207:Cytokines / Q000494:pharmacology*; D005155:Facial Nerve Diseases / Q000378:metabolism / Q000473:pathology; D005260:Female; D007839:Functional Laterality; D015870:Gene Expression / Q000187:drug effects; D007150:Immunohistochemistry / Q000379:methods; D008264:Macrophages / Q000502:physiology*; D051379:Mice; D008845:Microinjections / Q000379:methods; D009836:Oligodendroglia / Q000378:metabolism*; D011509:Proteoglycans / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D020426:Sciatic Neuropathy / Q000473:pathology* / Q000503:physiopathology; D013234:Stem Cells / Q000378:metabolism*; D000099216:Chondroitin Sulfate Proteoglycan 4
D000941:Antigens; D039481:CD11b Antigen; D016207:Cytokines; D011509:Proteoglycans; D000099216:Chondroitin Sulfate Proteoglycan 4